Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

ClinicalTrials.gov ID: NCT04643886

Public ClinicalTrials.gov record NCT04643886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103

Study identification

NCT ID
NCT04643886
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Enrollment
62 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 29, 2020
Primary completion
Feb 17, 2022
Completion
Mar 20, 2022
Last update posted
Sep 22, 2022

2020 – 2022

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
29
Facility City State ZIP Site status
Gemini Clinical Trial Site Phoenix Arizona 85020
Gemini Clinical Trial Site Bakersfield California 93309
Gemini Clinical Trial Site Beverly Hills California 90211
Gemini Clinical Trial Site Oxnard California 93036
Gemini Clinical Trial Site Poway California 92064
Gemini Clinical Trial Site Santa Barbara California 93103
Gemini Clinical Trial Site Santa Maria California 93454
Gemini Clinical Trial Site Golden Colorado 80401
Gemini Clinical Trial Site New London Connecticut 06320
Gemini Clinical Trial Site Palm Beach Gardens Florida 33410
Gemini Clinical Trial Site St. Petersburg Florida 33711
Gemini Clinical Trial Site Tallahassee Florida 32308
Gemini Clinical Trial Site Winter Haven Florida 33880
Gemini Clinical Trial Site Augusta Georgia 30909
Gemini Clinical Trial Site Marietta Georgia 30060
Gemini Clinical Trial Site Oak Park Illinois 60304
Gemini Clinical Trial Site Indianapolis Indiana 46290
Gemini Clinical Trial Site Chesterfield Missouri 63017
Gemini Clinical Trial Site St Louis Missouri 63144
Gemini Clinical Trial Site Reno Nevada 89502
Gemini Clinical Trial Site Bloomfield New Jersey 07003
Gemini Clinical Trial Site Asheville North Carolina 28803
Gemini Clinical Trial Site Charlotte North Carolina 28210
Gemini Clinical Trial Site Eugene Oregon 97401
Gemini Clinical Trial Site Rapid City South Dakota 57701
Gemini Clinical Trial Site Abilene Texas 79606
Gemini Clinical Trial Site Dallas Texas 75231
Gemini Clinical Trial Site The Woodlands Texas 77384
Gemini Clinical Trial Site Virginia Beach Virginia 23454

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04643886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 22, 2022 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04643886 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →